Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Tolerability and Efficacy of the First-InClass Anti-CD47 Antibody Magrolimab Combined With Azacitidine in Frontline Patients With TP53-Mutated Acute Myeloid Leukemia (AML): Phase 1b Results
Tolerability and Efficacy of the First-InClass Anti-CD47 Antibody Magrolimab Combined With Azacitidine in Frontline Patients With TP53-Mutated Acute Myeloid Leukemia (AML): Phase 1b Results Daver, N., Vyas, P., Kambhampati, S., Al Malki, M., Larson, R., Asch, A., Mannis, G., Chai-Ho, W., Tanaka, T., Bradley, T., Jeyakumar, D., Wang, E., Xing, G., Chao, M., Ramsingh, G., Renard, C., Lal, I., Zeidner, J., Sallman, D. CIG MEDIA GROUP, LP. 2022: S253-S254View details for Web of Science ID 000897948100179